查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715821

早产和胎膜早破检测市场（按类型、样本和最终用户划分）—2025-2030 年全球预测

Preterm Birth & PROM Testing Market by Type, Sample, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

早产和胎膜早破检测市场在 2023 年的价值为 15.5 亿美元，预计在 2024 年将成长至 16.4 亿美元，复合年增长率为 6.20%，预计到 2030 年将达到 23.6 亿美元。

执行摘要简介：为早产和胎膜早破检测做好准备

主要市场统计数据
基准年2023年 15.5亿美元
预计2024年 16.4亿美元
预测年份 2030 23.6亿美元
复合年增长率（%） 6.20%

在当今快速发展的医疗保健环境中，早产和胎膜早破 (PROM) 的早期发现和管理已成为临床医生、研究人员和决策者关注的重点。本报告深入探讨了诊断和预后测试方法的复杂情况，并强调了影响患者照护的传统方法和新兴方法。介绍探讨了早期发现和及时介入的临床重要性，并强调了先进的筛检技术如何有助于改善新生儿结果并降低相关的健康风险。透过这里提供的全面见解，读者将更深入地了解技术创新、不断变化的监管环境和不断发展的临床实践如何改变早产和胎膜早破检测的格局。本报告重点关注数据主导的分析和可操作的信息，利用强大的市场研究来识别可能重新定义临床方案和诊断准确性的趋势。它适合行业专家和关键决策者，他们希望透过对当前和未来趋势的整体观点来优化患者管理策略并提高护理标准。

改变潮流：早产和胎膜早破检测的创新和发展实践

在创新诊断技术和不断发展的临床实践的推动下，早产和胎膜早破检测领域正在转变。近年来，改进的成像技术和生化测试与先进的诊断工具相结合，显着提高了早产相关风险的检测率和准确性。在研究突破和多学科合作的推动下，临床医生越来越多地将新的生物标记和更复杂的筛检测试纳入常规护理中。此外，各地区的监管机构正在更新其指南以跟上这些技术进步的步伐，为快速采用创新测试方法创造有利环境。因此，医疗保健整体的相关人员看到测试敏感性和特异性正在加速提高，从而改善了患者的治疗效果。此外，数位健康解决方案和即时数据分析的结合使医疗保健专业人员能够做出更快、更明智的决策，从而提高早期诊断的价值。这些变化反映了降低早产和胎膜早破相关发病率和死亡率的承诺，同时也为个人化、预测性医疗介入开闢了新的途径。

关键细分洞察诊断方式和测试样本类型详情

我们的分析揭示了清晰的细分趋势，从而更清晰地描绘了市场的结构和演变。按类型检查市场格局，透过一系列诊断方式对市场进行评估，包括生化标记、弗宁测试、胎儿纤连蛋白、尼塔金测试、骨盆检查、汇集、超音波检查和子宫监测。特别值得注意的是生化标记物，结合蛋白质-1、白细胞介素(IL)-6 和胎盘 α-微球蛋白-1。除了基于技术的分割之外，我们还考虑基于样本的分割，重点关注从羊水、血液、尿液和阴道液中获得的诊断样本。此外，关键的最终用户细分将市场分为诊断实验室、医院/诊所和专科中心。这些细分见解凸显了塑造当前市场趋势驱动因素的各种测试方法、样本来源和应用程式设定的复杂性和相互关联性。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 糖尿病和高血压发生率增加导致早产
      • 更加重视开发就地检验解决方案
      • 扩大政府和医疗保健部门的努力，降低早产率
    • 限制因素
      • 人们越来越担心胎盘保护试验（PROMs）的假阳性结果
    • 机会
      • 公司加大对早产和胎膜早破检测解决方案开发的投资
      • PROM 测试研究和开发活动中的新合作努力
    • 任务
      • 早产和胎膜早破检测的严格规定和各种核准流程
  • 市场区隔分析
    • 类型：越来越多地使用生化标记物来早期发现和管理早产和胎膜早破
    • 样本：高特异性和敏感性将扩大羊膜穿刺术在临床实践中的应用
    • 最终用户：准确性和高容量检测正在推动诊断实验室中早产和胎膜早破检测的使用增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 早产和胎膜早破检测市场（按类型）

  • 生化标记
    • 胎儿球蛋白
    • C反应蛋白
    • 促皮质素释放激素
    • 白血球介素-1、白血球介素-2、白血球介素-8、肿瘤坏死因子-α
    • 胰岛素样生长因子结合蛋白质-1
    • 白细胞介素（IL）-6
    • 胎盘α-微球蛋白-1
  • 蕨类植物测试
  • 纤连蛋白
  • 尼塔金试验
  • 骨盆腔检查
  • 池化
  • 超音波
  • 子宫监测

7. 早产及胎膜早破检测市场（依样本）

  • 羊水
  • 血
  • 尿
  • 阴道分泌物

8. 早产和胎膜早破检测市场（依最终用户）

  • 诊断实验室
  • 医院和诊所
  • 专业中心

9. 美洲早产和胎停检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

10. 亚太地区早产及胎停检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

11. 欧洲、中东和非洲早产和胎膜早破检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • BillionToOne, Inc.
  • Biosynex SA
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • FUJIFILM Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • Hologic, Inc.
  • Igenomix India Private Limited
  • Illumina, Inc.
  • Koninklijke Philips NV
  • Laboratory Corporation of America Holdings
  • Medix Biochemica Group
  • Nanjing Liming Bio-products Co., Ltd.
  • Natera, Inc.
  • NX Prenatal, Inc.
  • Pro Lab Diagnostics Inc
  • Qiagen NV
  • Revvity, Inc.
  • Samsung Electronics Co., Ltd.
  • Sekisui Diagnostics, LLC
  • Sera prognostics, Inc.
  • Siemens Healthineers AG
  • The Cooper Companies, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-42653751E7E1

The Preterm Birth & PROM Testing Market was valued at USD 1.55 billion in 2023 and is projected to grow to USD 1.64 billion in 2024, with a CAGR of 6.20%, reaching USD 2.36 billion by 2030.

Executive Summary Introduction: Setting the Stage for Preterm Birth & PROM Testing

KEY MARKET STATISTICS
Base Year [2023] USD 1.55 billion
Estimated Year [2024] USD 1.64 billion
Forecast Year [2030] USD 2.36 billion
CAGR (%) 6.20%

In today's rapidly evolving healthcare environment, the early detection and management of preterm birth and PROM (premature rupture of membranes) have emerged as critical focal points for clinicians, researchers, and decision-makers alike. This report delves into the intricate landscape of diagnostic and prognostic testing approaches, shedding light on both traditional and emerging methodologies that shape patient care. The introduction explores the clinical importance of early detection and timely intervention, underlining how advanced testing techniques contribute to better neonatal outcomes and reduce associated health risks. As we navigate through the comprehensive insights provided herein, the reader will develop an understanding of how technological innovations, regulatory shifts, and evolving clinical practices are converging to transform the landscape of preterm birth and PROM testing. Emphasizing data-driven analysis and actionable intelligence, this report leverages robust market research to identify trends that have the potential to redefine clinical protocols and diagnostic accuracy. By establishing a holistic view of the current state and prospective trends, the content is tailored to both industry experts and key decision-makers seeking to optimize patient management strategies and drive forward the standards of care.

Transformative Shifts in the Landscape: Innovations and Evolving Practices in Preterm Birth & PROM Testing

The landscape of preterm birth and PROM testing is undergoing transformative shifts fueled by innovative diagnostic technologies and evolving clinical practices. Over recent years, the integration of advanced diagnostic tools with improved imaging techniques and biochemical testing has significantly enhanced the detection rates and accuracy of identifying risks associated with premature birth. Driven by research breakthroughs and cross-disciplinary collaborations, clinicians are increasingly incorporating novel biomarkers and more precise screening tests into routine practice. Moreover, regulatory bodies across various geographies have updated guidelines to accommodate these technological advances, fostering an environment that encourages rapid adoption of innovative testing methods. As a consequence, stakeholders across the healthcare continuum are witnessing accelerated developments in test sensitivity and specificity, leading to improved patient outcomes. Additionally, the convergence of digital health solutions and real-time data analytics has enabled practitioners to make swift, informed decisions, thereby reinforcing the value of early diagnostics. These transformative shifts collectively reflect a commitment to reducing the morbidity and mortality associated with preterm birth and PROM, while also opening new avenues for personalized and predictive healthcare interventions.

Key Segmentation Insights: A Detailed Look into Diagnostic Modalities and Sample Types in Testing

Our analysis identifies distinct segmentation trends that provide a clearer picture of the market's structure and evolution. When examining the landscape based on type, the market is evaluated across an array of diagnostic modalities including biochemical markers, the ferning test, fetal fibronectin, the nitazine test, pelvic exam, pooling, ultrasound, and uterine monitoring. Of particular note are biochemical markers, which have been further dissected into several sub-categories such as alpha-fetoprotein, C-reactive protein, corticotropin-releasing hormone, IL-1, IL-2, IL-8, TNF-a, insulin-like growth factor binding protein-1, interleukin (IL)-6, and placental alpha microglobulin-1. In addition to the technology-based segmentation, the analysis also considers sample-based divisions, focusing on diagnostic samples derived from amniotic fluid, blood, urine, and vaginal secretions, each of which provides unique insights into the diagnostic process. Furthermore, a critical end-user segmentation delineates the market into diagnostic laboratories, hospitals and clinics, and specialty centers. These segmentation insights collectively underscore the complexity and interconnectivity of the various testing approaches, sample sources, and application settings that are coalescing to form the drivers of current market trends.

Based on Type, market is studied across Biochemical Markers, Ferning Test, Fetal Fibronectin, Nitazine Test, Pelvic exam, Pooling, Ultrasound, and Uterine Monitoring. The Biochemical Markers is further studied across Alpha-fetoprotein, C-Reactive Protein, Corticotropin-Releasing Hormone, IL-1, IL-2, IL-8, TNF-a, Insulin-like Growth Factor Binding Protein-1, Interleukin (IL)-6, and Placental Alpha Microglobulin-1.

Based on Sample, market is studied across Amniotic Fluid, Blood, Urine, and Vaginal Secretions.

Based on End-User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Specialty Centers.

Key Regional Insights: Understanding Market Dynamics Across Global Territories

Regional dynamics play an essential role in shaping the market trends for preterm birth and PROM testing. The market reveals distinct characteristics and varying rates of adoption across different geographies. In the Americas, strong investments in healthcare technologies, coupled with advanced infrastructure, have positioned the region at the forefront of testing innovations. Regions encompassing Europe, the Middle East, and Africa exhibit a wide spectrum of market maturity, where the interplay of established healthcare systems and emerging economies stimulates both sophisticated testing advancements and rapid adoption of novel diagnostics. In Asia-Pacific, rising healthcare expenditure and a burgeoning patient population are driving the rapid integration of state-of-the-art diagnostics into clinical practice. These developments are further boosted by regional government initiatives focused on enhancing maternal and neonatal health outcomes. Collectively, these regional insights highlight the need for tailored market strategies that account for varying economic landscapes, regulatory environments, and cultural factors, which in turn dictate the pace at which testing methodologies are embraced and implemented.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights: Leading Innovators and Market Influencers in Diagnostic Testing

The market for preterm birth and PROM testing is increasingly competitive, with several leading companies driving innovation and shaping market dynamics. Industry leaders such as Abbott Laboratories, BillionToOne, Inc., Biosynex SA, Eurofins Scientific SE, and F. Hoffmann-La Roche AG have consistently pushed the boundaries in diagnostic accuracy and test efficacy. These companies are complemented by organizations like FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., and Hologic, Inc., whose contributions in imaging and analytical solutions are pivotal in refining test protocols. Further notable players include Igenomix India Private Limited, Illumina, Inc., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, and Medix Biochemica Group, all of which emphasize the importance of robust technology integration. Leaders like Nanjing Liming Bio-products Co., Ltd., Natera, Inc., NX Prenatal, Inc., Pro Lab Diagnostics Inc, and Qiagen N.V. are continuously evolving to meet clinical demands. Additional contributions from Revvity, Inc., Samsung Electronics Co., Ltd., Sekisui Diagnostics, LLC, Sera Prognostics, Inc., Siemens Healthineers AG, The Cooper Companies, Inc., and Thermo Fisher Scientific Inc. further underscore the multi-faceted competitive landscape. This competitive milieu reflects a relentless pursuit of innovation, improved patient outcomes, and operational excellence in diagnostic testing.

The report delves into recent significant developments in the Preterm Birth & PROM Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, BillionToOne, Inc., Biosynex SA, Eurofins Scientific SE, F. Hoffmann-La Roche AG, FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., Hologic, Inc., Igenomix India Private Limited, Illumina, Inc., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Medix Biochemica Group, Nanjing Liming Bio-products Co., Ltd., Natera, Inc., NX Prenatal, Inc., Pro Lab Diagnostics Inc, Qiagen N.V., Revvity, Inc., Samsung Electronics Co., Ltd., Sekisui Diagnostics, LLC, Sera prognostics, Inc., Siemens Healthineers AG, The Cooper Companies, Inc., and Thermo Fisher Scientific Inc.. Actionable Recommendations for Industry Leaders: Strategies to Enhance Diagnostic Value and Market Positioning

Industry leaders are encouraged to adopt proactive and innovative strategies to maintain competitive advantage in the dynamic market of preterm birth and PROM testing. Embracing technology-driven advancements is imperative in today's clinical environment. Companies should invest in continuous research and development to explore novel biomarkers and testing methodologies, ensuring that new diagnostic solutions anticipate future clinical needs. Furthermore, strategic collaborations with academic institutions and healthcare providers can expedite the translation of cutting-edge research into reliable, market-ready solutions. Emphasis should be placed on integrating digital health platforms and real-time data analytics not only to improve test turnaround times but also to enhance predictive accuracy through personalized patient profiles. In addition, expanding geographical reach into regions with emerging markets can create new revenue channels while addressing unmet clinical needs. Cost-effective operational strategies, coupled with a robust regulatory compliance framework, will aid in ensuring that testing solutions remain accessible and trustworthy. Ultimately, leaders must balance rapid innovation with patient safety and data integrity, fostering a culture of excellence that positions their organizations as pioneers in the field of preterm birth and PROM testing.

Conclusion: Synthesizing Insights to Shape the Future of Diagnostic Testing in Preterm Birth and PROM

The comprehensive insights presented in this report underscore the multifaceted nature of the preterm birth and PROM testing market. From transformative technological shifts to detailed segmentation analyses and regional dynamics, it becomes clear that the landscape is marked by both complexity and opportunity. Integrating advanced diagnostic tools with refined clinical practices has paved the way for improved patient care and better outcomes in maternal and neonatal health. As the market continues to evolve, the interplay between innovative testing methodologies and strategic industry positioning will be fundamental to driving progress and addressing unmet clinical needs. This synthesis of data, trends, and actionable strategies offers a clear vision for the future, emphasizing the importance of agility, sustained investment in research, and cross-industry partnerships. Ultimately, the shared goal remains to enhance diagnostic precision, thereby contributing to more informed decision-making and improved quality of care for patients globally.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of preterm births owing to the increasing rates of diabetes and hypertension
      • 5.1.1.2. Rising focus on the development of point-of-care testing solutions
      • 5.1.1.3. Growing government and healthcare initiatives aimed at reducing preterm birth rates
    • 5.1.2. Restraints
      • 5.1.2.1. Rising concerns about false positive results of PROM tests
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising investment by companies for the development of preterm birth & PROM testing solutions
      • 5.1.3.2. Emerging collaborative efforts in research and development activities for PROM tests
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations and varying approval processes for preterm birth & PROM tests
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing use of biochemical markers for early detection and management of preterm birth & PROM
    • 5.2.2. Sample: Expanding the use of amniotic fluid testing in clinical settings owing to high specificity and sensitivity
    • 5.2.3. End-User: Growing use of preterm birth & PROM tests in diagnostic laboratories owing to accuracy and mass testing
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Preterm Birth & PROM Testing Market, by Type

  • 6.1. Introduction
  • 6.2. Biochemical Markers
    • 6.2.1. Alpha-fetoprotein
    • 6.2.2. C-Reactive Protein
    • 6.2.3. Corticotropin-Releasing Hormone
    • 6.2.4. IL-1, IL-2, IL-8, TNF-a
    • 6.2.5. Insulin-like Growth Factor Binding Protein-1
    • 6.2.6. Interleukin (IL)-6
    • 6.2.7. Placental Alpha Microglobulin-1
  • 6.3. Ferning Test
  • 6.4. Fetal Fibronectin
  • 6.5. Nitazine Test
  • 6.6. Pelvic exam
  • 6.7. Pooling
  • 6.8. Ultrasound
  • 6.9. Uterine Monitoring

7. Preterm Birth & PROM Testing Market, by Sample

  • 7.1. Introduction
  • 7.2. Amniotic Fluid
  • 7.3. Blood
  • 7.4. Urine
  • 7.5. Vaginal Secretions

8. Preterm Birth & PROM Testing Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals & Clinics
  • 8.4. Specialty Centers

9. Americas Preterm Birth & PROM Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Preterm Birth & PROM Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Preterm Birth & PROM Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Novocuff Inc. secures USD 26 million in Series A funding to advance pioneering device addressing preterm birth and PROM with global impact
    • 12.3.2. Clarius Mobile Health's FDA-cleared Clarius OB AI tool enhances prenatal care with automated fetal biometry in the U.S. and Canada
    • 12.3.3. Lumos Diagnostics secures an additional USD 5 million from Hologic to enhance preterm birth diagnostics with advanced fetal fibronectin test
    • 12.3.4. Samsung Medison acquires Sonio SAS to integrate advanced AI technologies with ultrasound systems
    • 12.3.5. Natera Inc. unveils revolutionary cell-free DNA RhD test improving RhD-negative pregnancy care and conserving RhIg resources
    • 12.3.6. Revvity unveils NGS panel workflow to enhance newborn screening capabilities
    • 12.3.7. BillionToOne launches a new non-invasive prenatal test for preterm birth risk and PROM testing
    • 12.3.8. Cord Blood Registry (CBR) and Fulgent Genetics introduce advanced genetic testing services
    • 12.3.9. Bloomlife and PeriGen collaborate to address maternal and fetal health needs in underserved regions
    • 12.3.10. BillionToOne and Janssen collaborate on phase 3 AZALEA clinical trial of nipocalimab for HDFN
    • 12.3.11. Hologic collaborates with AAGL and Inovus Medical to advance OB-GYN training with advanced simulation technology
    • 12.3.12. GE HealthCare receives USD 44 million Gates Foundation grant to develop AI-assisted ultrasound for improving maternal and child healthcare in low-and-middle-income countries
  • 12.4. Strategy Analysis & Recommendation
    • 12.4.1. Hologic, Inc.
    • 12.4.2. Laboratory Corporation of America Holdings
    • 12.4.3. Revvity, Inc.
    • 12.4.4. Siemens Healthineers AG

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. BillionToOne, Inc.
  • 3. Biosynex SA
  • 4. Eurofins Scientific SE
  • 5. F. Hoffmann-La Roche AG
  • 6. FUJIFILM Holdings Corporation
  • 7. GE HealthCare Technologies, Inc.
  • 8. Hologic, Inc.
  • 9. Igenomix India Private Limited
  • 10. Illumina, Inc.
  • 11. Koninklijke Philips N.V.
  • 12. Laboratory Corporation of America Holdings
  • 13. Medix Biochemica Group
  • 14. Nanjing Liming Bio-products Co., Ltd.
  • 15. Natera, Inc.
  • 16. NX Prenatal, Inc.
  • 17. Pro Lab Diagnostics Inc
  • 18. Qiagen N.V.
  • 19. Revvity, Inc.
  • 20. Samsung Electronics Co., Ltd.
  • 21. Sekisui Diagnostics, LLC
  • 22. Sera prognostics, Inc.
  • 23. Siemens Healthineers AG
  • 24. The Cooper Companies, Inc.
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. PRETERM BIRTH & PROM TESTING MARKET MULTI-CURRENCY
  • FIGURE 2. PRETERM BIRTH & PROM TESTING MARKET MULTI-LANGUAGE
  • FIGURE 3. PRETERM BIRTH & PROM TESTING MARKET RESEARCH PROCESS
  • FIGURE 4. PRETERM BIRTH & PROM TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PRETERM BIRTH & PROM TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PRETERM BIRTH & PROM TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PRETERM BIRTH & PROM TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PRETERM BIRTH & PROM TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ALPHA-FETOPROTEIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY C-REACTIVE PROTEIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY CORTICOTROPIN-RELEASING HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IL-1, IL-2, IL-8, TNF-A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INTERLEUKIN (IL)-6, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PLACENTAL ALPHA MICROGLOBULIN-1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY FERNING TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY FETAL FIBRONECTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY NITAZINE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PELVIC EXAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY POOLING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY UTERINE MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMNIOTIC FLUID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY VAGINAL SECRETIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SINGAPORE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 95. SINGAPORE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH KOREA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH KOREA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. TAIWAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 102. TAIWAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 103. TAIWAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. THAILAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 106. THAILAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 107. THAILAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. VIETNAM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 110. VIETNAM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 111. VIETNAM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. DENMARK PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 119. DENMARK PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 120. DENMARK PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. EGYPT PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 123. EGYPT PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 124. EGYPT PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FINLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 127. FINLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 128. FINLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. FRANCE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 131. FRANCE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 132. FRANCE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. GERMANY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 135. GERMANY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 136. GERMANY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ISRAEL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 139. ISRAEL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 140. ISRAEL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. ITALY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 143. ITALY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 144. ITALY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NETHERLANDS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 147. NETHERLANDS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 148. NETHERLANDS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NIGERIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 151. NIGERIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 152. NIGERIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. NORWAY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 155. NORWAY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 156. NORWAY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. POLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 159. POLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 160. POLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. QATAR PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 163. QATAR PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 164. QATAR PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. RUSSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 167. RUSSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 168. RUSSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SAUDI ARABIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 171. SAUDI ARABIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 172. SAUDI ARABIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SPAIN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 179. SPAIN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 180. SPAIN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWEDEN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 183. SWEDEN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 184. SWEDEN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. SWITZERLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 187. SWITZERLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 188. SWITZERLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. TURKEY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 191. TURKEY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 192. TURKEY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED ARAB EMIRATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED KINGDOM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 200. UNITED KINGDOM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. PRETERM BIRTH & PROM TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 202. PRETERM BIRTH & PROM TESTING MARKET, FPNV POSITIONING MATRIX, 2023